PF-Atlas › Clinical Trials › NCT02412111

A Phase 3 Study of Tezacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis , Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor

Ivacaftor · Phase 3

Registry ID
NCT02412111
Phase
Phase 3
Status
Completed
Drug / intervention
Ivacaftor
Sponsor
Vertex Pharmaceuticals Incorporated
Start
2015-06
Enrollment
156
Locations
68

About this trial

This is a Phase 3, randomized, double-blind, ivacaftor-controlled, parallel-group, multicenter study of tezacaftor in combination with ivacaftor in subjects aged 12 years and older with CF who are heterozygous for the F508del-CFTR mutation and a second CFTR allele with a gating defect that is clinically demonstrated to be ivacaftor responsive.

View NCT02412111 on ClinicalTrials.gov →

Explore related

All Ivacaftor trialsAll IPF trials

Related trials

ivacaftor — NCT02445053Ivacaftor — NCT00953706Ivacaftor — NCT01614457Ivacaftor — NCT01705145Ivacaftor — NCT02934698Ivacaftor — NCT03068312
Medical disclaimer. This page summarizes public trial data for NCT02412111 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.